Literature DB >> 16037564

The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.

Thierry Claudel1, Bart Staels, Folkert Kuipers.   

Abstract

Bile acids are the end products of cholesterol metabolism. They are synthesized in the liver and secreted via bile into the intestine, where they aid in the absorption of fat-soluble vitamins and dietary fat. Subsequently, bile acids return to the liver to complete their enterohepatic circulation. The Farnesoid X receptor (FXR) is a member of the nuclear receptor superfamily and has emerged as a key player in the control of multiple metabolic pathways. On its activation by bile acids, FXR regulates bile acid synthesis, conjugation, and transport, as well as various aspects of lipid and glucose metabolism. This review summarizes recent advances in deciphering the role of FXR in the context of hepatic lipid and glucose homeostasis and discusses the potential of FXR as a pharmacological target for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037564     DOI: 10.1161/01.ATV.0000178994.21828.a7

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  130 in total

1.  A comparative study of genome-wide transcriptional profiles of primary hepatocytes in collagen sandwich and monolayer cultures.

Authors:  Yeonhee Kim; Christopher D Lasher; Logan M Milford; T M Murali; Padmavathy Rajagopalan
Journal:  Tissue Eng Part C Methods       Date:  2010-06-07       Impact factor: 3.056

2.  Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system.

Authors:  D P Poole; C Godfrey; F Cattaruzza; G S Cottrell; J G Kirkland; J C Pelayo; N W Bunnett; C U Corvera
Journal:  Neurogastroenterol Motil       Date:  2010-03-12       Impact factor: 3.598

Review 3.  New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.

Authors:  James L Boyer
Journal:  J Hepatol       Date:  2006-12-18       Impact factor: 25.083

4.  Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease.

Authors:  Zhao-Xia Yang; Wei Shen; Hang Sun
Journal:  Hepatol Int       Date:  2010-08-12       Impact factor: 6.047

5.  The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin.

Authors:  Miao Hu; Sandra S H Lui; Lai-Shan Tam; Edmund K Li; Brian Tomlinson
Journal:  J Lipid Res       Date:  2012-04-24       Impact factor: 5.922

6.  Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner.

Authors:  Josep Maria Del Bas; Marie-Louise Ricketts; Montserrat Vaqué; Esther Sala; Helena Quesada; Anna Ardevol; M Josepa Salvadó; Mayte Blay; Lluís Arola; David D Moore; Gerard Pujadas; Juan Fernandez-Larrea; Cinta Bladé
Journal:  Mol Nutr Food Res       Date:  2009-07       Impact factor: 5.914

7.  The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells.

Authors:  Yewei Xing; Karla Saner-Amigh; Yasuhiro Nakamura; Margaret M Hinshelwood; Bruce R Carr; J Ian Mason; William E Rainey
Journal:  Mol Cell Endocrinol       Date:  2008-11-18       Impact factor: 4.102

8.  No Gut No Gain! Enteral Bile Acid Treatment Preserves Gut Growth but Not Parenteral Nutrition-Associated Liver Injury in a Novel Extensive Short Bowel Animal Model.

Authors:  Gustavo Villalona; Amber Price; Keith Blomenkamp; Chandrashekhara Manithody; Saurabh Saxena; Thomas Ratchford; Matthew Westrich; Vindhya Kakarla; Shruthika Pochampally; William Phillips; Nicole Heafner; Niraja Korremla; Jose Greenspon; Miguel A Guzman; Ajay Kumar Jain
Journal:  JPEN J Parenter Enteral Nutr       Date:  2018-04-27       Impact factor: 4.016

Review 9.  Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology.

Authors:  Tirthadipa Pradhan-Sundd; Satdarshan Pal Monga
Journal:  Gene Expr       Date:  2019-01-15

10.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.